Value Health. 2017 Dec;20(10):1345-1354. doi: 10.1016/j.jval.2017.05.023. Epub 2017 Jul 6.
Effects of Transitioning to Medicare Part D on Access to Drugs for Medical Conditions among Dual Enrollees with Cancer.
Adams AS1, Madden JM2, Zhang F3, Lu CY3, Ross-Degnan D3, Lee A4, Soumerai SB3, Gilden D4, Chawla N5, Griggs JJ6.
Abstract
OBJECTIVES:
To evaluate the impact of transitioning from Medicaid to Medicare Part D drug coverage on the use of noncancer treatments among dual enrollees with cancer.
METHODS:
We leveraged a representative 5% national sample of all fee-for-service dual enrollees in the United States (2004-2007) to evaluate the impact of the removal of caps on the number of reimbursable prescriptions per month (drug caps) under Part D on 1) prevalence and 2) average days' supply dispensed for antidepressants, antihypertensives, and lipid-lowering agents overall and by race (white and black).
RESULTS:
The removal of drug caps was associated with increased use of lipid-lowering medications (days' supply 3.63; 95% confidence interval [CI] 1.57-5.70). Among blacks in capped states, we observed increased use of lipid-lowering therapy (any use 0.08 percentage points; 95% CI 0.05-0.10; and days' supply 4.01; 95% CI 2.92-5.09) and antidepressants (days' supply 2.20; 95% CI 0.61-3.78) and increasing trends in antihypertensive use (any use 0.01 percentage points; 95% CI 0.004-0.01; and days' supply 1.83; 95% CI 1.25-2.41). The white-black gap in the use of lipid-lowering medications was immediately reduced (-0.09 percentage points; 95% CI -0.15 to -0.04). We also observed a reversal in trends toward widening white-black differences in antihypertensive use (level -0.08 percentage points; 95% CI -0.12 to -0.05; and trend -0.01 percentage points; 95% CI -0.02 to -0.01) and antidepressant use (-0.004 percentage points; 95% CI -0.01 to -0.0004).
CONCLUSIONS:
Our findings suggest that the removal of drug caps under Part D had a modest impact on the treatment of hypercholesterolemia overall and may have reduced white-black gaps in the use of lipid-lowering and antidepressant therapies.
Copyright © 2017. Published by Elsevier Inc.
KEYWORDS:
Medicaid; Medicare; Part D; comorbidity; disparities; dual eligibles
- PMID:
- 29241894
- PMCID:
- PMC5734096
- [Available on 2018-12-01]
- DOI:
- 10.1016/j.jval.2017.05.023
- [Indexed for MEDLINE]
No hay comentarios:
Publicar un comentario